Trial Profile
An open-label study on effectiveness and tolerability of atomoxetine as perceived by patients, parents, and physicians in children with attention-deficit/hyperactivity disorder in Germany
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jul 2006
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 30 Jul 2006 Status change
- 13 Nov 2005 New trial record.